Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;14(4):667-679.
doi: 10.3233/JPD-230390.

Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson's Disease Diagnosis and Duration

Affiliations

Association of Misfolded α-Synuclein Derived from Neuronal Exosomes in Blood with Parkinson's Disease Diagnosis and Duration

Eva Schaeffer et al. J Parkinsons Dis. 2024.

Abstract

Background: Misfolded α-synuclein can be detected in blood samples of Parkinson's disease (PD) patients by a seed amplification assay (SAA), but the association with disease duration is not clear, yet.

Objective: In the present study we aimed to elucidate whether seeding activity of misfolded α-synuclein derived from neuronal exosomes in blood is associated with PD diagnosis and disease duration.

Methods: Cross-sectional samples of PD patients were analyzed and compared to samples of age- and gender-matched healthy controls using a blood-based SAA. Presence of α-synuclein seeding activity and differences in seeding parameters, including fluorescence response (in arbitrary units) at the end of the amplification assay (F60) were analyzed. Additionally, available PD samples collected longitudinally over 5-9 years were included.

Results: In the cross-sectional dataset, 79 of 80 PD patients (mean age 69 years, SD = 8; 56% male) and none of the healthy controls (n = 20, mean age 70 years, SD = 10; 55% male) showed seeding activity (sensitivity 98.8%). When comparing subgroups divided by disease duration, longer disease duration was associated with lower α-synuclein seeding activity (F60: p < 0.001). In the longitudinal analysis 10/11 patients showed a gradual decrease of α-synuclein seeding activity over time.

Conclusions: This study confirms the high sensitivity of the blood-based α-synuclein SAA applied here. The negative association of α-synuclein seeding activity in blood with disease duration makes this parameter potentially interesting as biomarker for future studies on the pathophysiology of disease progression in PD, and for biologically oriented trials in this field.

Keywords: Parkinson’s disease; alpha-synuclein; biomarker.

PubMed Disclaimer

Conflict of interest statement

ES received grants from the University of Kiel (intramural research funding) and Germany society for Parkinson’s Disease (DPG e.V.), and speaker honoraria from Bayer Vital GmbH, Novartis Pharma GmbH, BIAL GmbH and the Movement Disorder Society outside the submitted work. AK has received research grants from the Michael J. Fox Foundation outside the submitted work. CS, CD, JB, and JW have nothing to report. WM has served on advisory boards of AbbVie, Biogen, Lundbeck, Market Access & Pricing Strategy GmbH, Orion Corporation, Techspert.io and Critical Path for Parkinson's Consortium and has received speaker’s honoraria from AbbVie, Bayer, GlaxoSmithKline, Licher MT, Neuro-Kolleg Online-Live, Rölke Pharma, Takeda, UCB Pharma GmbH, Kyowa Kirin International, and Ology Medical Education outside the submitted work. He was reimbursed consulting fees from EMEA Medical Education Steering Committee for Parkinson’s disease and received grants from Lundbeck, Neuroalliance, European Union, German Federal Ministry of Education of Research, Michael J Fox Foundation, Robert Bosch Foundation, and Sivantos outside the submitted work. DB has received grants or contracts from the German Research Society (DFG), German Parkinson’s Disease Association (dPV), Michael J. Fox Foundation, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, Novartis Pharma GmbH, Damp Foundation, and Lundbeck and has received speaker’s honoraria from AbbVie, Biogen, BIAL, UCB Pharma GmbH, Novartis Pharma GmbH, and Desitin outside the submitted work. She has served on advisory boards of Biogen, BIAL, UCB Pharma GmbH and AC Immune SA outside the submitted work. The TREND-Study is being and was supported by University Hospital Tübingen, German Center for Neurodegenerative Diseases (DZNE), Hertie Institute for Clinical Brain Research (HIH), Christian-Albrechts-University of Kiel, and University Hospital Schleswig-Holstein. Until 2017, subprojects were co-funded by Centre for Integrative Neuroscience (CIN), TEVA Pharmaceutical Industries Ltd, UCb, Janssen Pharmaceuticals, Inc. and International Parkinson Fonds. DB is an Editorial Board Member of this journal but was not involved in the peer-review process nor had access to any information regarding its peer-review.

Figures

Fig. 1
Fig. 1
α-Synuclein seeding in Parkinson’s disease cohorts (n = 79). A) α-Synuclein seeding in Parkinson’s disease cohorts with different disease duration (n = 79). The boxplots indicate the median (range) Thioflavin T signal intensity after 60 hours (in arbitrary units) of the four different Parkinson’s disease duration groups. B) Scatter diagram showing the correlation of α-synuclein seeding (Thioflavin T signal intensity after 60 hours) and disease duration in all analyzed individuals with Parkinson’s disease (n = 79). F60, Thioflavin T signal intensity after 60 hours; PD, Parkinson’s disease.
Fig. 2
Fig. 2
Longitudinal α-synuclein seeding of individuals with Parkinson’s disease. Presentation of longitudinal values of the α-synuclein seed amplification assay in n = 11 individuals with Parkinson’s disease at three timepoints. α-Synucleins seeding is displayed as Thioflavin T signal intensity after 60 hours (F60). Each colored line represents longitudinal values of one individual with Parkinson’s disease (mean of both replicates, error bars indicate the standard deviation of both replicates). F60, Thioflavin T signal intensity after 60 hours.
Fig. 3
Fig. 3
Examples of longitudinal seeding in Parkinson’s disease. Both boxes show individual seeding curves of one individual with Parkinson’s disease measured at three different timepoints (shown are both replicates). The x-axis displays the hours of the α-synuclein seed amplification assay, the y-axis displays the increasing Thioflavin T signal intensity. hrs, hours; ThT, Thioflavin T.

Similar articles

Cited by

References

    1. Srivastava A, Alam P, Caughey B (2022) RT-QuIC and related assays for detecting and quantifying prion-like pathological seeds of α-synuclein. Biomolecules 12, 576. - PMC - PubMed
    1. Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, Singh N, Tatsuoka C, Appleby B, Zhu X, Xu R, Haroutunian V, Zou W-Q, Ma J, Chen SG (2021) Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9, 62. - PMC - PubMed
    1. Brockmann K, Quadalti C, Lerche S, Rossi M, Wurster I, Baiardi S, Roeben B, Mammana A, Zimmermann M, Hauser A-K, Deuschle C, Schulte C, Waniek K, Lachmann I, Sjödin S, Brinkmalm A, Blennow K, Zetterberg H, Gasser T, Parchi P (2021) Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun 9, 175. - PMC - PubMed
    1. Compta Y, Painous C, Soto M, Pulido-Salgado M, Fernández M, Camara A, Sánchez V, Bargalló N, Caballol N, Pont-Sunyer C, Buongiorno M, Martin N, Basora M, Tio M, Giraldo DM, Pérez-Soriano A, Zaro I, Muñoz E, Martí MJ, Valldeoriola F (2022) Combined CSF α-SYNRT-QuIC, CSF NFL and midbrain-pons planimetry in degenerativeparkinsonisms: From bedside to bench, and back again. Parkinsonism Relat Disord 99, 33–41. - PubMed
    1. Donadio V, Wang Z, Incensi A, Rizzo G, Fileccia E, Vacchiano V, Capellari S, Magnani M, Scaglione C, Stanzani Maserati M, Avoni P, Liguori R, Zou W (2021) In vivo diagnosis of synucleinopathies. Neurology 96, e2513–e2524. - PMC - PubMed

Publication types